- Home
- SAVA vs LFT Comparison
SAVA vs LFT Comparison
Compare SAVA & LFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- LFT
- Stock Information
- Founded
- SAVA 1998
- LFT 2012
- Country
- SAVA United States
- LFT United States
- Employees
- SAVA N/A
- LFT N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- LFT Real Estate Investment Trusts
- Sector
- SAVA Health Care
- LFT Real Estate
- Exchange
- SAVA Nasdaq
- LFT Nasdaq
- Market Cap
- SAVA 135.9M
- LFT 136.0M
- IPO Year
- SAVA N/A
- LFT N/A
- Fundamental
- Price
- SAVA $2.75
- LFT $2.58
- Analyst Decision
- SAVA Buy
- LFT Buy
- Analyst Count
- SAVA 3
- LFT 3
- Target Price
- SAVA $111.50
- LFT $2.50
- AVG Volume (30 Days)
- SAVA 3.4M
- LFT 164.6K
- Earning Date
- SAVA 02-26-2025
- LFT 11-12-2024
- Dividend Yield
- SAVA N/A
- LFT 15.50%
- EPS Growth
- SAVA N/A
- LFT 52.72
- EPS
- SAVA N/A
- LFT 0.35
- Revenue
- SAVA N/A
- LFT $36,400,239.00
- Revenue This Year
- SAVA N/A
- LFT N/A
- Revenue Next Year
- SAVA N/A
- LFT N/A
- P/E Ratio
- SAVA N/A
- LFT $7.44
- Revenue Growth
- SAVA N/A
- LFT 25.67
- 52 Week Low
- SAVA $2.23
- LFT $2.16
- 52 Week High
- SAVA $42.20
- LFT $2.79
- Technical
- Relative Strength Index (RSI)
- SAVA 30.54
- LFT 49.21
- Support Level
- SAVA $2.65
- LFT $2.39
- Resistance Level
- SAVA $2.83
- LFT $2.64
- Average True Range (ATR)
- SAVA 0.24
- LFT 0.08
- MACD
- SAVA 0.59
- LFT -0.00
- Stochastic Oscillator
- SAVA 52.75
- LFT 51.35
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.